Glück Conviction Score™ ⓘ
NTRA
Natera, Inc.
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
45,5
92 neu, 298 erhöht, -4028006K $ netto
Aktivist
11,2
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 206.64 | +2.6 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 205.44 | +3.2 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 6 Tagen @ 222.10 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 212.12 | EMA50: 208.42 | |
| MACD-Histogramm | Bullisch | 10 % | 0.285 | Bullisch | |
| RSI(14) | Neutral | 10 % | 51.0 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 49.7 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 13.1 | +DI: 22.6 / −DI: 19.7 | |
| Z-Score(60) | Neutral | 5 % | 0.79 | In Range | |
| 52W-Position | Neutral | 5 % | 64.9 % | Hoch 254.40 / Tief 133.66 | |
| Bollinger(20,2σ) | Neutral | 5 % | 56.0 % | Upper 229.96 / Mid 209.65 / Lower 189.33 | |
| LinReg-Slope(60) | Neutral | 10 % | +0.2694 | R²=0.26 / annualisiert +33.1 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.174 | 218,11 | -692.276,06 | -101,3% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -4.694 | 217,30 | -1.020.023,10 | -149,3% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -116 | 218,82 | -25.382,54 | -3,7% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.016 | 216,06 | -651.646,31 | -95,4% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.300 | 214,83 | -279.279,00 | -40,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.758 | 219,08 | -604.224,29 | -88,4% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.503 | 213,44 | -534.250,33 | -78,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.409 | 226,97 | -773.740,39 | -113,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.351 | 217,04 | -510.260,10 | -74,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.742 | 218,28 | -380.251,95 | -55,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.630 | 224,99 | -366.736,63 | -53,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.400 | 220,19 | -528.450,00 | -77,3% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -832 | 212,42 | -176.732,36 | -25,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -5.499 | 216,13 | -1.188.523,07 | -173,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.006 | 222,25 | -445.827,28 | -65,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.500 | 223,34 | -1.451.680,10 | -212,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.443 | 223,91 | -323.101,12 | -47,3% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.751 | 226,15 | -1.526.719,75 | -223,4% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -213 | 219,34 | -46.719,42 | -6,8% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -14.885 | 221,58 | -3.298.289,75 | -482,7% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -10.100 | 219,78 | -2.219.745,68 | -324,9% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -413 | 218,84 | -90.382,78 | -13,2% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.850 | 222,79 | -634.964,04 | -92,9% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -572 | 220,67 | -126.221,75 | -18,5% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.450 | 223,83 | -548.374,93 | -80,3% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.802 | 217,52 | -391.970,86 | -57,4% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -26.411 | 218,69 | -5.775.771,41 | -845,3% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -21.304 | 220,94 | -4.706.946,24 | -688,9% | |
| 2026-05-26 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.652 | 202,84 | -335.091,35 | -49,0% | |
| 2026-05-26 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -1.438 | 202,84 | -291.683,63 | -42,7% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -290 | 202,58 | -58.748,87 | -8,6% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -30 | 202,84 | -6.085,20 | -0,9% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -96 | 199,43 | -19.145,72 | -2,8% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -285 | 202,68 | -57.764,63 | -8,5% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -360 | 201,19 | -72.429,23 | -10,6% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -9 | 203,30 | -1.829,66 | -0,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -345 | 201,11 | -69.384,30 | -10,2% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -85 | 199,52 | -16.958,98 | -2,5% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 205,43 | -41.086,00 | -6,0% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -1.150 | 210,35 | -241.896,75 | -35,4% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -900 | 207,24 | -186.516,99 | -27,3% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -700 | 208,13 | -145.690,02 | -21,3% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 209,57 | -41.914,50 | -6,1% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -948 | 205,22 | -194.548,56 | -28,5% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.454 | 241,39 | -350.981,06 | -51,4% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.697 | 206,77 | -350.888,69 | -51,4% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.887 | 206,77 | -596.944,99 | -87,4% | |
| 2026-05-04 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -722 | 206,16 | -148.847,52 | -21,8% | |
| 2026-05-04 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -482 | 210,49 | -101.456,18 | -14,8% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -560 | 200,95 | -112.533,29 | -16,5% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -405 | 206,16 | -83.494,80 | -12,2% | |
| 2026-05-01 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -291 | 206,16 | -59.992,56 | -8,8% | |
| 2026-05-01 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -902 | 206,16 | -185.956,32 | -27,2% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -865 | 204,47 | -176.862,83 | -25,9% | |
| 2026-05-01 | Sheena Jonathan | Director | Open Market Sale | -107 | 206,16 | -22.059,12 | -3,2% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -150 | 206,93 | -31.039,50 | -4,5% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -520 | 201,60 | -104.832,21 | -15,3% | |
| 2026-05-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -330 | 206,16 | -68.032,80 | -10,0% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -505 | 203,32 | -102.674,33 | -15,0% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -400 | 205,31 | -82.123,00 | -12,0% | |
| 2026-05-01 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -313 | 206,16 | -64.528,08 | -9,4% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.000 | 193,78 | -193.779,00 | -28,4% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -2.266 | 196,22 | -444.623,42 | -65,1% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -500 | 192,13 | -96.064,30 | -14,1% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -300 | 190,12 | -57.034,50 | -8,3% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.070 | 194,82 | -208.459,54 | -30,5% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -200 | 197,26 | -39.452,00 | -5,8% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -805 | 196,99 | -158.575,02 | -23,2% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -23,0% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -23,0% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -997 | 203,75 | -203.138,75 | -29,7% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -917 | 204,39 | -187.425,63 | -27,4% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -188 | 204,39 | -38.425,32 | -5,6% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.222 | 204,39 | -249.764,58 | -36,6% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -285 | 203,75 | -58.068,75 | -8,5% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.272 | 203,75 | -462.920,00 | -67,8% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.566 | 204,39 | -728.854,74 | -106,7% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -988 | 204,39 | -201.937,32 | -29,6% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -873 | 203,75 | -177.873,75 | -26,0% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.185 | 204,39 | -242.202,15 | -35,4% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,66 | -149.748,00 | -21,9% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,59 | -149.692,95 | -21,9% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.200 | 203,83 | -244.590,96 | -35,8% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.048 | 201,32 | -210.983,99 | -30,9% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -3.213 | 203,07 | -652.470,34 | -95,5% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -952 | 203,31 | -193.551,69 | -28,3% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.000 | 202,36 | -202.363,80 | -29,6% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -300 | 200,79 | -60.236,04 | -8,8% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.778 | 202,01 | -359.167,02 | -52,6% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.909 | 205,00 | -391.349,96 | -57,3% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -140 | 199,82 | -27.975,40 | -4,1% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 198,49 | -46.644,19 | -6,8% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 199,88 | -46.971,10 | -6,9% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -239 | 198,85 | -47.526,32 | -7,0% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -371 | 200,97 | -74.561,35 | -10,9% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -280 | 200,90 | -56.252,64 | -8,2% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -1.814 | 198,65 | -360.355,09 | -52,7% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -300 | 196,27 | -58.880,01 | -8,6% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -956 | 197,84 | -189.135,14 | -27,7% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -16.457 | 197,22 | -3.245.611,69 | -475,0% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -24.814 | 196,23 | -4.869.290,92 | -712,7% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -900 | 192,43 | -173.185,02 | -25,3% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.300 | 194,17 | -446.592,61 | -65,4% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.875 | 195,42 | -952.695,90 | -139,4% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -100 | 190,07 | -19.007,08 | -2,8% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -254 | 198,02 | -50.297,18 | -7,4% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -300 | 190,68 | -57.203,07 | -8,4% | |
| 2026-03-13 | Chapman Rowan E | Director | Open Market Sale | -122 | 191,38 | -23.348,36 | -3,4% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.504 | 189,50 | -4.075.005,85 | -596,4% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -17.037 | 187,63 | -3.196.631,87 | -467,8% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.100 | 191,22 | -210.344,97 | -30,8% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -13.883 | 190,46 | -2.644.206,16 | -387,0% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.476 | 188,54 | -4.049.190,27 | -592,6% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -22.063 | 190,53 | -4.203.720,75 | -615,2% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -9.896 | 191,55 | -1.895.594,63 | -277,4% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.043 | 193,58 | -1.363.388,87 | -199,5% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -8.091 | 186,75 | -1.510.989,40 | -221,1% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -8.579 | 192,79 | -1.653.957,42 | -242,1% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.082 | 194,57 | -794.218,00 | -116,2% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -100 | 195,32 | -19.532,00 | -2,9% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.886 | 189,64 | -547.306,81 | -80,1% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.809 | 187,52 | -1.089.299,61 | -159,4% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -6.451 | 188,52 | -1.216.111,56 | -178,0% | |
| 2026-03-10 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -785 | 204,13 | -160.244,17 | -23,5% | |
| 2026-03-10 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.745 | 204,13 | -356.211,56 | -52,1% | |
| 2026-03-10 | Sheena Jonathan | Director | Open Market Sale | -127 | 204,13 | -25.924,85 | -3,8% | |
| 2026-03-10 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -915 | 204,13 | -186.781,42 | -27,3% | |
| 2026-03-10 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -707 | 204,13 | -144.321,82 | -21,1% | |
| 2026-03-10 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -5.623 | 204,13 | -1.147.838,17 | -168,0% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -2.900 | 194,77 | -564.832,42 | -82,7% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.998 | 198,04 | -395.693,51 | -57,9% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.600 | 195,80 | -313.272,64 | -45,8% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -400 | 193,73 | -77.491,16 | -11,3% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.500 | 196,94 | -295.406,10 | -43,2% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -931 | 198,83 | -185.114,27 | -27,1% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.594 | 200,11 | -318.971,04 | -46,7% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -2.400 | 200,42 | -481.012,08 | -70,4% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -475 | 200,97 | -95.459,75 | -14,0% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -470 | 198,50 | -93.292,93 | -13,7% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -100 | 201,20 | -20.120,00 | -2,9% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -100 | 202,85 | -20.285,00 | -3,0% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -365 | 201,18 | -73.429,50 | -10,7% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.122 | 199,17 | -223.472,89 | -32,7% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.463 | 200,24 | -493.192,60 | -72,2% | |
| 2026-02-03 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.268 | 230,77 | -292.613,82 | -42,8% | |
| 2026-02-03 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -4.971 | 227,45 | -1.130.639,04 | -165,5% | |
| 2026-02-03 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -700 | 225,25 | -157.673,53 | -23,1% | |
| 2026-02-03 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -1.179 | 230,77 | -272.075,47 | -39,8% | |
| 2026-02-03 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -2.415 | 231,14 | -558.203,10 | -81,7% | |
| 2026-02-03 | Sheena Jonathan | Director | Open Market Sale | -435 | 230,77 | -100.384,08 | -14,7% | |
| 2026-02-03 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.639 | 230,77 | -378.228,75 | -55,4% | |
| 2026-02-03 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -4.725 | 230,77 | -1.090.378,80 | -159,6% | |
| 2026-02-03 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.334 | 230,77 | -307.844,51 | -45,1% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -100 | 234,00 | -23.400,00 | -3,4% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.631 | 229,08 | -1.519.059,98 | -222,3% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -600 | 233,24 | -139.942,02 | -20,5% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -878 | 229,96 | -201.902,86 | -29,5% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -850 | 232,33 | -197.476,51 | -28,9% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -16 | 234,00 | -3.744,00 | -0,5% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -80 | 228,50 | -18.280,00 | -2,7% | |
| 2026-02-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -576 | 230,84 | -132.963,78 | -19,5% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -20.079 | 230,95 | -4.637.172,77 | -678,7% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -41.847 | 230,03 | -9.625.956,61 | -1408,8% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -9.197 | 232,41 | -2.137.444,42 | -312,8% | |
| 2026-02-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -7.445 | 233,31 | -1.737.006,35 | -254,2% | |
| 2026-01-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -876 | 230,92 | -202.289,16 | -29,6% | |
| 2026-01-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -991 | 229,94 | -227.866,48 | -33,3% | |
| 2026-01-28 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.648 | 237,66 | -866.992,44 | -126,9% | |
| 2026-01-28 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.200 | 237,66 | -285.194,88 | -41,7% | |
| 2026-01-28 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.000 | 237,66 | -237.662,40 | -34,8% | |
| 2026-01-28 | Sheena Jonathan | Director | Open Market Sale | -191 | 237,66 | -45.393,52 | -6,6% | |
| 2026-01-28 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.176 | 237,44 | -279.232,73 | -40,9% | |
| 2026-01-28 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.237 | 237,66 | -293.988,39 | -43,0% | |
| 2026-01-28 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -928 | 237,66 | -220.550,71 | -32,3% | |
| 2026-01-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.322 | 240,53 | -558.513,68 | -81,7% | |
| 2026-01-27 | Sheena Jonathan | Director | Open Market Sale | -291 | 240,53 | -69.994,61 | -10,2% | |
| 2026-01-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.013 | 240,53 | -243.658,21 | -35,7% | |
| 2026-01-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -784 | 240,53 | -188.576,54 | -27,6% | |
| 2026-01-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -784 | 240,53 | -188.576,54 | -27,6% | |
| 2026-01-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -886 | 240,53 | -213.110,73 | -31,2% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -160 | 242,31 | -38.769,81 | -5,7% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -160 | 243,59 | -38.973,95 | -5,7% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -390 | 244,87 | -95.500,31 | -14,0% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -50 | 245,62 | -12.281,00 | -1,8% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -185 | 243,49 | -45.045,74 | -6,6% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -200 | 242,23 | -48.446,40 | -7,1% | |
| 2026-01-23 | Sheena Jonathan | Director | Open Market Sale | -355 | 244,78 | -86.897,04 | -12,7% | |
| 2026-01-21 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -602 | 235,00 | -141.470,00 | -20,7% | |
| 2026-01-21 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -339 | 235,00 | -79.665,00 | -11,7% | |
| 2026-01-21 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -36.573 | 242,67 | -8.875.115,05 | -1298,9% | |
| 2026-01-21 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -293 | 235,00 | -68.855,00 | -10,1% | |
| 2026-01-21 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -438 | 235,00 | -102.930,00 | -15,1% | |
| 2026-01-21 | Sheena Jonathan | Director | Open Market Sale | -2.470 | 234,12 | -578.265,78 | -84,6% | |
| 2026-01-21 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.590 | 235,00 | -373.650,00 | -54,7% | |
| 2026-01-21 | Sheena Jonathan | Director | Open Market Sale | -93 | 235,00 | -21.855,00 | -3,2% | |
| 2026-01-21 | Sheena Jonathan | Director | Open Market Sale | -600 | 235,82 | -141.490,98 | -20,7% | |
| 2026-01-20 | Sheena Jonathan | Director | Open Market Sale | -2.981 | 234,74 | -699.755,17 | -102,4% | |
| 2026-01-20 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -23.948 | 234,74 | -5.621.515,20 | -822,7% | |
| 2026-01-20 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -17.806 | 234,74 | -4.179.751,95 | -611,7% | |
| 2026-01-20 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -71.932 | 234,74 | -16.885.202,59 | -2471,3% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | 12.854.334 | 0 | 12.854.334 | 2.944.799.683 | Neu | +100,0% | |
| VANGUARD GROUP INC | 12.306.424 | 0 | 12.306.424 | 2.819.278.675 | Neu | +100,0% | |
| BlackRock, Inc. | 10.677.338 | 10.859.441 | -182.103 | 2.135.360.953 | Reduziert | -1,7% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 0 | 6.008.496 | 1.201.639.115 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | 4.976.325 | -207.732 | 953.670.913 | Reduziert | -4,2% | |
| STATE STREET CORP | 3.417.472 | 3.225.879 | 191.593 | 683.460.225 | Aufgestockt | +5,9% | |
| FARALLON CAPITAL MANAGEMENT LLC | 3.207.366 | 0 | 3.207.366 | 641.441.126 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.775.928 | 2.608.644 | 167.284 | 553.818.995 | Aufgestockt | +6,4% | |
| FMR LLC | 2.554.254 | 1.475.988 | 1.078.266 | 510.825.126 | Aufgestockt | +73,1% | |
| COATUE MANAGEMENT LLC | 2.541.842 | 2.633.334 | -91.492 | 508.342.981 | Reduziert | -3,5% | |
| Castle Hook Partners LP | 2.529.810 | 2.167.869 | 361.941 | 505.936.702 | Aufgestockt | +16,7% | |
| FRANKLIN RESOURCES INC | 2.485.325 | 2.534.553 | -49.228 | 497.040.120 | Reduziert | -1,9% | |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | 2.599.299 | -325.308 | 442.564.045 | Reduziert | -12,5% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.040.106 | 2.047.963 | -7.857 | 407.990.494 | Reduziert | -0,4% | |
| NORGES BANK | 1.625.553 | 0 | 1.625.553 | 372.397.937 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 1.756.472 | 1.822.508 | -66.036 | 351.276.835 | Reduziert | -3,6% | |
| Sofinnova Investments, Inc. | 1.550.280 | 1.550.280 | 0 | 310.040.497 | Unverändert | 0,0% | |
| Capital World Investors | 1.467.975 | 1.433.094 | 34.881 | 293.580.320 | Aufgestockt | +2,4% | |
| MORGAN STANLEY | 1.354.335 | 1.234.154 | 120.181 | 270.853.971 | Aufgestockt | +9,7% | |
| Invesco Ltd. | 1.258.377 | 1.329.166 | -70.789 | 251.662.787 | Reduziert | -5,3% | |
| RTW INVESTMENTS, LP | 1.250.000 | 1.500.000 | -250.000 | 249.987.500 | Reduziert | -16,7% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.191.732 | 1.179.939 | 11.793 | 238.334.483 | Aufgestockt | +1,0% | |
| MAVERICK CAPITAL LTD | 1.171.633 | 944.028 | 227.605 | 234.314.884 | Aufgestockt | +24,1% | |
| FEDERATED HERMES, INC. | 1.090.030 | 1.019.195 | 70.835 | 217.995.100 | Aufgestockt | +7,0% | |
| Clearbridge Investments, LLC | 893.322 | 790.101 | 103.221 | 178.655.567 | Aufgestockt | +13,1% | |
| GOLDMAN SACHS GROUP INC | 822.831 | 756.781 | 66.050 | 164.557.971 | Aufgestockt | +8,7% | |
| NORTHERN TRUST CORP | 788.445 | 775.774 | 12.671 | 157.681.116 | Aufgestockt | +1,6% | |
| GILDER GAGNON HOWE & CO LLC | 755.275 | 828.300 | -73.025 | 151.047.391 | Reduziert | -8,8% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 754.729 | 714.692 | 40.037 | 150.938.268 | Aufgestockt | +5,6% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 752.936 | 741.742 | 11.194 | 150.579.670 | Aufgestockt | +1,5% | |
| PointState Capital LP | 739.879 | 715.495 | 24.384 | 147.968.401 | Aufgestockt | +3,4% | |
| BANK OF AMERICA CORP /DE/ | 733.669 | 875.373 | -141.704 | 146.726.383 | Reduziert | -16,2% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 712.748 | 674.403 | 38.345 | 142.542.473 | Aufgestockt | +5,7% | |
| Sumitomo Mitsui Trust Group, Inc. | 692.368 | 711.394 | -19.026 | 138.466.676 | Reduziert | -2,7% | |
| ARK Investment Management LLC | 684.255 | 731.110 | -46.855 | 136.844.067 | Reduziert | -6,4% | |
| MAPLELANE CAPITAL, LLC | 474.862 | 0 | 474.862 | 135.793.211 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 631.338 | 252.930 | 378.408 | 126.261.287 | Aufgestockt | +149,6% | |
| Chevy Chase Trust Holdings, LLC | 587.030 | 582.015 | 5.015 | 117.400.131 | Aufgestockt | +0,9% | |
| RAYMOND JAMES FINANCIAL INC | 591.043 | 614.224 | -23.181 | 112.321.645 | Reduziert | -3,8% | |
| FIRST TRUST ADVISORS LP | 528.798 | 319.742 | 209.056 | 105.754.264 | Aufgestockt | +65,4% | |
| VICTORY CAPITAL MANAGEMENT INC | 515.238 | 556.740 | -41.502 | 103.042.447 | Reduziert | -7,5% | |
| JANE STREET GROUP, LLC | 499.977 | 187.541 | 312.436 | 99.990.400 | Aufgestockt | +166,6% | |
| Legal & General Group Plc | 498.141 | 363.121 | 135.020 | 99.623.224 | Aufgestockt | +37,2% | |
| AMERICAN CENTURY COMPANIES INC | 496.904 | 540.694 | -43.790 | 99.375.831 | Reduziert | -8,1% | |
| D. E. Shaw & Co., Inc. | 491.336 | 553.607 | -62.271 | 98.262.287 | Reduziert | -11,2% | |
| AGF MANAGEMENT LTD | 491.262 | 474.130 | 17.132 | 98.247.487 | Aufgestockt | +3,6% | |
| Nuveen, LLC | 474.608 | 479.184 | -4.576 | 94.916.853 | Reduziert | -1,0% | |
| Allspring Global Investments Holdings, LLC | 463.477 | 454.498 | 8.979 | 94.183.161 | Aufgestockt | +2,0% | |
| Point72 Asset Management, L.P. | 444.199 | 125.312 | 318.887 | 88.835.358 | Aufgestockt | +254,5% | |
| Amova Asset Management Americas, Inc. | 423.424 | 471.084 | -47.660 | 84.684.800 | Reduziert | -10,1% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | 13.386.667 | 12.854.334 | +4,1% | 2.501.165.314 | 11,68 |
| BlackRock, Inc. | 10.677.338 | 10.859.441 | -1,7% | 2.135.360.953 | 9,97 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 0 | +100,0% | 1.201.639.115 | 5,61 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | 4.976.325 | -4,2% | 953.670.913 | 4,45 |
| STATE STREET CORP | 3.417.472 | 3.225.879 | +5,9% | 683.460.225 | 3,19 |
| FARALLON CAPITAL MANAGEMENT LLC | 3.207.366 | 0 | +100,0% | 641.441.126 | 3,00 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.775.928 | 2.608.644 | +6,4% | 553.818.995 | 2,59 |
| FMR LLC | 2.554.254 | 1.475.988 | +73,1% | 510.825.126 | 2,39 |
| COATUE MANAGEMENT LLC | 2.541.842 | 2.633.334 | -3,5% | 508.342.981 | 2,37 |
| Castle Hook Partners LP | 2.529.810 | 2.167.869 | +16,7% | 505.936.702 | 2,36 |
| FRANKLIN RESOURCES INC | 2.485.325 | 2.534.553 | -1,9% | 497.040.120 | 2,32 |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | 2.599.299 | -12,5% | 442.564.045 | 2,07 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.040.106 | 2.047.963 | -0,4% | 407.990.494 | 1,91 |
| FRED ALGER MANAGEMENT, LLC | 1.756.472 | 1.822.508 | -3,6% | 351.276.835 | 1,64 |
| Sofinnova Investments, Inc. | 1.550.280 | 1.550.280 | 0,0% | 310.040.497 | 1,45 |
| Capital World Investors | 1.467.975 | 1.433.094 | +2,4% | 293.580.320 | 1,37 |
| MORGAN STANLEY | 1.354.335 | 1.234.154 | +9,7% | 270.853.971 | 1,26 |
| Invesco Ltd. | 1.258.377 | 1.329.166 | -5,3% | 251.662.787 | 1,18 |
| RTW INVESTMENTS, LP | 1.250.000 | 1.500.000 | -16,7% | 249.987.500 | 1,17 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.191.732 | 1.179.939 | +1,0% | 238.334.483 | 1,11 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 742 | 140,9 | 24.023 |
| 31.12.2025 | ✓ | 764 | 138,5 | 27.512 |
| 30.09.2025 | ✓ | 686 | 151,6 | 20.955 |
| 30.06.2025 | ✓ | 649 | 133,2 | 19.085 |
| 31.03.2025 | ✓ | 594 | 136,8 | 16.658 |
| 31.12.2024 | ✓ | 583 | 130,5 | 18.351 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 1.625.553 | 372.397.937 |
| Kinetic Partners Management, LP | 273.300 | 62.610.297 |
| TUDOR INVESTMENT CORP ET AL | 272.415 | 62.407.552 |
| Civilization Ventures Management, LLC | 228.458 | 52.337.443 |
| Ilex Capital Partners (UK) LLP | 117.702 | 26.964.351 |
| BRAIDWELL LP | 111.500 | 25.543.535 |
| Davern Capital Partners, LP | 78.650 | 18.017.929 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 78.473 | 17.977.000 |
| Foresite Capital Management VI LLC | 67.356 | 15.430.586 |
| Foresite Capital Management V, LLC | 67.356 | 15.430.586 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| COATUE MANAGEMENT LLC | 2.633.334 | 2.463.008 | +1446.1 % | 603.270.486 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.976.325 | 2.420.263 | +94.7 % | 1.140.026.295 |
| JPMORGAN CHASE & CO | 12.854.334 | 1.225.420 | +10.5 % | 2.944.799.683 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.179.939 | 620.954 | +111.1 % | 270.312.226 |
| T. Rowe Price Investment Management, Inc. | 498.359 | 498.341 | +2768561.1 % | 114.170 |
| AGF MANAGEMENT LTD | 474.130 | 466.804 | +6371.9 % | 108.618.442 |
| D. E. Shaw & Co., Inc. | 553.607 | 421.450 | +318.9 % | 126.825.827 |
| Castle Hook Partners LP | 2.167.869 | 420.621 | +24.1 % | 496.637.110 |
| FMR LLC | 1.475.988 | 362.642 | +32.6 % | 338.134.121 |
| Robeco Institutional Asset Management B.V. | 343.768 | 338.100 | +5965.1 % | 78.753.811 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 10.871.989 | -1.075.426 | -9.0 % | 2.490.665 |
| CITADEL ADVISORS LLC | 196.946 | -880.020 | -81.7 % | 45.118.359 |
| Duquesne Family Office LLC | 2.511.357 | -803.175 | -24.2 % | 575.327 |
| FRED ALGER MANAGEMENT, LLC | 1.822.508 | -629.271 | -25.7 % | 417.518.357 |
| RTW INVESTMENTS, LP | 1.500.000 | -500.000 | -25.0 % | 343.635.000 |
| PointState Capital LP | 715.495 | -410.910 | -36.5 % | 163.912.750 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 252.930 | -408.298 | -61.7 % | 57.943.734 |
| MAVERICK CAPITAL LTD | 944.028 | -388.723 | -29.2 % | 216.267.375 |
| GOLDMAN SACHS GROUP INC | 756.781 | -344.742 | -31.3 % | 173.370.959 |
| AMERICAN CENTURY COMPANIES INC | 540.694 | -302.733 | -35.9 % | 123.867.649 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,08 % | 7.205.939 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -9,13 pp | |
| 17.02.2026 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.872.702 | -1,10 pp | |
| 23.01.2026 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 9,10 % | 12.825.640 | +1,40 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 8,90 % | 12.191.814 | +1,10 pp | |
| 22.07.2025 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 7,70 % | 10.594.256 | +2,70 pp | |
| 14.05.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.554.721 | +2,70 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,60 % | 7.565.936 | Neu | |
| 14.02.2025 | T. Rowe Price Associates, Inc. | Passiv (13G) | 5,10 % | 6.742.428 | Neu | |
| 10.02.2025 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,00 % | 6.668.519 | +0,70 pp | |
| 14.11.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 3,20 % | 4.011.957 | -2,70 pp | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | 0,00 pp | |
| 22.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | +1,50 pp | |
| 07.06.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 4,30 % | 5.335.516 | -2,30 pp | |
| 14.02.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 5,90 % | 7.076.157 | -2,30 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,13 % | 10.971.895 | +0,12 pp | |
| 31.01.2024 | . BlackRock, Inc. | Passiv (13G) | 5,20 % | 6.305.838 | +0,30 pp | |
| 23.01.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 6,60 % | 7.964.473 | +1,00 pp | |
| 06.04.2023 | . BlackRock, Inc. | Passiv (13G/A) | 4,90 % | 5.509.188 | -0,20 pp | |
| 14.02.2023 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 8,20 % | 8.972.721 | +1,00 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,01 % | 9.945.514 | +0,78 pp | |
| 03.02.2023 | . BlackRock, Inc. | Passiv (13G) | 5,10 % | 5.566.743 | +0,20 pp | |
| 23.01.2023 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 5,60 % | 6.211.632 | +0,30 pp | |
| 09.06.2022 | . BlackRock, Inc. | Passiv (13G) | 4,90 % | 4.706.415 | -2,50 pp | |
| 14.02.2022 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 7,20 % | 6.805.028 | -0,08 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,23 % | 7.785.953 | -0,44 pp | |
| 03.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 7,40 % | 7.010.757 | +0,10 pp | |
| 24.01.2022 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,30 % | 5.025.967 | Neu |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 22.09.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 22.08.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 20.11.2024 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Natera, Inc., ein Diagnostikunternehmen, entwickelt und vermarktet molekulare Testdienste weltweit. Das Unternehmen bietet Panorama, einen nicht-invasiven Pränataltest zur Prüfung auf chromosomale Abnormitäten eines Fötus durch einen Blutabstrich der Mutter, ebenso wie Zwillingsschwangerschaften bezüglich Zygosität; Vistara, einen Screening-Test für Einzelgen-Mutationen zur Identifikation von Einzelgen-Störungen; Horizon-Träger-Screening zur Bestimmung des Trägerstatus für verschiedene genetische Erkrankungen; und Spectrum zur Identifikation von chromosomalen Anomalien oder vererbten genetischen Erkrankungen während eines In-vitro-Befruchtungszyklus. Das Unternehmen bietet auch Anora-Fehlgeburtstest-Produkte zur Analyse fetaler Chromosomen zur Bestimmung der Ursache einer Fehlgeburt; und nicht-invasive Vaterschaftstest-Produkte zur Bestimmung der Vaterschaft mittels Schwangerschaft durch einen Blutabstrich von der schwangeren Mutter und dem mutmaßlichen Vater. Zusätzlich bietet es Constellation an, ein cloudbasiertes Softwareprodukt, das Laborkundenlabore befähigt, über die Cloud auf die Algorithmen und Bioinformatik des Unternehmens zuzugreifen, um Tests zu validieren und einzuführen; Signatera, eine zirkulierende Tumor-DNA-Technologie, die auf einen generischen Satz von Mutationen unabhängig vom Tumor eines Individuums prüft; und Prospera zur Bewertung der Transplantatablehnung. Das Unternehmen bietet Produkte über seine direkte Vertriebskraft, sowie über ein Netzwerk von ungefähr 100 Labor- und Vertriebspartnern an. Das Unternehmen hat eine Partnerschaftsvereinbarung mit BGI Genomics Co., Ltd. zur Entwicklung, Herstellung und Vermarktung von NGS-basierten genetischen Test-Assays; und Foundation Medicine, Inc. zur Entwicklung und Vermarktung personalisierter Überwachungs-Assays für zirkulierende Tumor-DNA. Das Unternehmen war früher als Gene Security Network, Inc. bekannt und änderte seinen Namen 2012 in Natera, Inc.. Natera, Inc. wurde 2003 gegründet und hat seinen Sitz in Austin, Texas.
Unternehmen & Branche
| Name | Natera, Inc. |
|---|---|
| Ticker | NTRA |
| CIK | 0001604821 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | 632307104 |
|---|---|
| ISIN | US6323071042 |
| Typ | Common Stock |
| Marktkapitalisierung | 30,62 Mrd. USD |
| Beta | 1,56 |
Bewertung
| KBV (P/B) | 17,88 vs. 13,60 (2021) ▲ |
|---|---|
| KUV (P/S) | 13,28 vs. 14,21 (2021) ▼ |
| FCF-Rendite | 0,4 % vs. -4,2 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | -13,4 % vs. -74,8 % (2021) ▲ |
|---|---|
| Nettomarge | -9,0 % vs. -75,4 % (2021) ▲ |
| ROIC | -10,8 % vs. -44,9 % (2021) ▲ |
| Zinsdeckungsgrad | -76,2 vs. -56,4 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 13,60 | 6,33 | 9,79 | 17,57 | 18,69 | |
| KUV (P/S) | 14,21 | 5,45 | 6,92 | 12,37 | 13,88 | |
| FCF-Rendite | -4,2 % | -10,7 % | -3,8 % | 0,3 % | 0,3 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | -74,8 % | -66,0 % | -41,2 % | -13,1 % | -13,4 % | |
| Nettomarge | -75,4 % | -66,8 % | -40,2 % | -11,2 % | -9,0 % | |
| ROIC | -44,9 % | -47,6 % | -36,0 % | -13,8 % | -10,8 % | |
| Zinsdeckungsgrad | -56,4 | -58,1 | -35,3 | -20,8 | -76,2 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 696.644.000 | -85.091.000 | -0,60 | 2.614.398.000 | 1.774.018.000 |
| 2025-12-31 | 10-K | 2.306.113.000 | -208.160.000 | -1,52 | 2.398.344.000 | 1.712.413.000 |
| 2025-09-30 | 10-Q | 592.183.000 | -87.544.000 | -0,64 | 1.821.482.000 | 1.252.188.000 |
| 2025-06-30 | 10-Q | 546.600.000 | -100.938.000 | -0,74 | 1.757.066.000 | 1.246.182.000 |
| 2025-03-31 | 10-Q | 501.830.000 | -66.936.000 | -0,50 | 1.732.366.000 | 1.239.675.000 |
| 2024-12-31 | 10-K | 1.696.911.000 | -190.426.000 | -1,53 | 1.660.735.000 | 1.195.420.000 |
| 2024-09-30 | 10-Q | 439.758.000 | -31.592.000 | -0,26 | 1.590.947.000 | 878.525.000 |
| 2024-06-30 | 10-Q | 413.351.000 | -37.464.000 | -0,30 | 1.516.989.000 | 836.520.000 |
| 2024-03-31 | 10-Q | 367.741.000 | -67.599.000 | -0,56 | 1.468.205.000 | 794.111.000 |
| 2023-12-31 | 10-K | 1.082.571.000 | -434.801.000 | -3,78 | 1.441.699.000 | 765.327.000 |
| 2023-09-30 | 10-Q | 268.306.000 | -109.030.000 | -0,95 | 1.446.520.000 | 784.658.000 |
| 2023-06-30 | 10-Q | 261.404.000 | -110.803.000 | -0,97 | 1.247.893.000 | 596.147.000 |
| 2023-03-31 | 10-Q | 241.756.000 | -136.937.000 | -1,23 | 1.318.880.000 | 650.573.000 |
| 2022-12-31 | 10-K | 820.222.000 | -547.799.000 | -5,57 | 1.394.474.000 | 705.744.000 |
| 2022-09-30 | 10-Q | 210.637.000 | -121.480.000 | -1,25 | 1.009.112.000 | 361.621.000 |
| 2022-06-30 | 10-Q | 198.200.000 | -145.151.000 | -1,50 | 1.066.976.000 | 444.582.000 |
| 2022-03-31 | 10-Q | 194.133.000 | -138.595.000 | -1,45 | 1.144.664.000 | 542.335.000 |
| 2021-12-31 | 10-K | 625.486.000 | -471.716.000 | -5,21 | 1.236.487.000 | 653.304.000 |
| 2021-09-30 | 10-Q | 158.116.000 | -151.273.000 | -1,63 | 1.311.374.000 | 759.017.000 |
| 2021-06-30 | 10-Q | 142.026.000 | -116.026.000 | -1,32 | 849.956.000 | 299.110.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 2,3 Mrd. | 1,7 Mrd. | 1,1 Mrd. | 797,3 Mio. | 567,1 Mio. | 99,6 % | +36,2% | |
| Licensing And Other | 10,3 Mio. | 11,8 Mio. | 14,0 Mio. | 22,9 Mio. | 58,3 Mio. | 0,4 % | -13,0% |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 2,3 Mrd. | 1,7 Mrd. | 1,0 Mrd. | 785,8 Mio. | 590,9 Mio. | 98,2 % | +36,6% | |
| Europe Middle East India And Africa | 24,5 Mio. | 23,9 Mio. | 22,8 Mio. | 16,6 Mio. | 20,4 Mio. | 1,1 % | +2,5% | |
| Americas Excluding Us | 9,4 Mio. | 6,6 Mio. | 4,9 Mio. | 3,7 Mio. | 4,0 Mio. | 0,4 % | +41,3% | |
| Other Geographic Areas | 8,0 Mio. | 8,7 Mio. | 7,2 Mio. | 14,0 Mio. | 10,1 Mio. | 0,3 % | -7,5% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 696,6 Mio. USD | -0,60 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 592,2 Mio. USD | -0,64 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 546,6 Mio. USD | -0,74 |
| Q1 2025 | 31.03.2025 | 08.05.2026 | 501,8 Mio. USD | -0,50 |
| Q3 2024 | 30.09.2024 | 07.11.2025 | 439,8 Mio. USD | -0,26 |
| Q2 2024 | 30.06.2024 | 08.08.2025 | 413,4 Mio. USD | -0,30 |
| Q1 2024 | 31.03.2024 | 09.05.2025 | 367,7 Mio. USD | -0,56 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | 268,3 Mio. USD | -0,95 |
| Q2 2023 | 30.06.2023 | 09.08.2024 | 261,4 Mio. USD | -0,97 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 27.02.2026 | 10-K | 31.12.2025 | 58 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 10.05.2023 | 10-Q | 31.03.2023 | 40 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (05.06.2026)
HOCH Abgang Schlüsselpersonen (01.04.2026)
HOCH Abgang Schlüsselpersonen (05.06.2026)
HOCH Abgang Schlüsselpersonen (01.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-24 | 571 | 201,14 | 114.851 |
| 2026-04-21 | 516 | 207,74 | 107.194 |
| 2026-04-17 | 967 | 196,11 | 189.638 |
| 2026-04-15 | 622 | 214,64 | 133.506 |
| 2026-04-08 | 188 | 209,27 | 39.343 |
| 2026-04-06 | 21 | 207,98 | 4.368 |
| 2026-03-31 | 83.324 | 186,84 | 15.568.256 |
| 2026-03-24 | 6 | 200,09 | 1.201 |
| 2026-03-11 | 834 | 198,95 | 165.924 |
| 2026-03-02 | 7.751 | 208,04 | 1.612.518 |
| 2026-02-10 | 12 | 210,58 | 2.527 |
| 2026-01-29 | 3 | 235,93 | 708 |
| 2026-01-21 | 86 | 234,85 | 20.197 |
| 2026-01-15 | 53 | 239,19 | 12.677 |
| 2026-01-12 | 1.238 | 234,31 | 290.076 |
| 2026-01-09 | 1.287 | 239,56 | 308.314 |
| 2026-01-08 | 1.154 | 254,40 | 293.578 |
| 2026-01-06 | 7.421 | 237,42 | 1.761.894 |
| 2025-12-31 | 7.408 | 229,98 | 1.703.692 |
| 2025-12-29 | 1 | 233,74 | 234 |
| 2025-12-24 | 35.188 | 235,40 | 8.283.255 |
| 2025-12-23 | 3.326 | 235,57 | 783.506 |
| 2025-12-22 | 43.790 | 231,96 | 10.157.528 |
| 2025-12-19 | 507 | 224,74 | 113.943 |
| 2025-12-18 | 487 | 225,49 | 109.814 |